HighPoint Resources (HPR) – PRNewswire
-
Q32 Bio and Horizon Therapeutics plc Announce Dosing of First Patient in Phase 2 Trial of ADX-914 for Atopic Dermatitis
-
HemoShear Therapeutics Advancing Novel Modulators Against Second Target for Horizon Therapeutics' Gout Discovery Pipeline
-
Q32 Bio and Horizon Therapeutics Announce Collaboration in Autoimmune Diseases
-
ACELYRIN Appoints Melanie Gloria as Chief Operating Officer
-
HemoShear Therapeutics Advancing Several Novel Compounds for Horizon Therapeutics plc Gout Discovery Pipeline
-
HemoShear Therapeutics Advances Second Novel Drug Target into Horizon Therapeutics plc Early Discovery Pipeline for Gout
-
Horizon Therapeutics plc and Halozyme Therapeutics, Inc. Enter Global Collaboration and License Agreement for ENHANZE® Technology
-
AGC Biologics and Horizon Therapeutics plc Expand Partnership
-
HemoShear Therapeutics Achieves Milestone in Exclusive Drug Discovery Collaboration with Horizon Therapeutics in Gout
-
Register Now for EnerCom's 25th Anniversary of The Oil & Gas Conference®, August 17-19, 2020
-
S&P Dow Jones Indices Announces Tyler Technologies, Bio-Rad Laboratories and Teledyne Technologies Set to Join S&P 500; Others to Join S&P MidCap 400 and S&P SmallCap 600
-
EnerCom Dallas 2020 Energy Investment Conference Set to Welcome Hundreds of Energy Industry Executives to Texas
-
Day Two Keynote Speaker, Charlie Riedl with CLNG, Announced for EnerCom Dallas Energy Investment Conference, February 11-12, 2020
-
Day One Keynote Speaker, Chris Wright, Announced for EnerCom Dallas Energy Investment Conference, February 11-12, 2020
-
One-on-One Meeting Scheduling Opens and Presenting Company Line-up is Announced for EnerCom Dallas Energy Investment Conference, February 11-12, 2020
-
Presenting Company Line-Up Announced for EnerCom Dallas Energy Investment Conference, February 11-12, 2020
-
Registration is Open for EnerCom Dallas Energy Investment Conference, February 11-12, 2020
Back to HPR Stock Lookup
